Bio-Rad Laboratories (BIO-B) Receivables - Other (2019 - 2026)

Bio-Rad Laboratories (BIO-B) has 8 years of Receivables - Other data on file, last reported at $13.3 million in Q1 2026.

• Receivables - Other for Q1 2026 came in at $13.3 million, down 2.92% year-over-year; the trailing twelve-month figure through Mar 2026 was $13.3 million (down 2.92% YoY), and the FY2025 annual result was $11.9 million, down 9.16% from the prior year.
• Receivables - Other rose to $13.3 million in Q1 2026 per BIO-B's latest filing, from $11.9 million in the prior quarter.
• Over five years, Receivables - Other peaked at $14.8 million in Q1 2023 and troughed at $6.3 million in Q2 2022.
• A 5-year average of $10.9 million and a median of $11.2 million in 2023 frame the typical range for Receivables - Other.
• The sharpest annual moves came in 2022 and 2025: Receivables - Other surged 427.27% in 2022, then slipped 17.35% in 2025.
• A 5-year view of Receivables - Other shows it stood at $11.6 million in 2022, then rose by 2.59% to $11.9 million in 2023, then climbed by 10.08% to $13.1 million in 2024, then dropped by 9.16% to $11.9 million in 2025, then climbed by 11.76% to $13.3 million in 2026.
• Business Quant data shows BIO-B's Receivables - Other at $13.3 million in Q1 2026, $11.9 million in Q4 2025, and $9.5 million in Q3 2025.